Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of dotinurad vs allopurinol in gout-associated hyperuricemia
2024-520206-19-00Phase 3Authorised
- Sponsor
- Crystalys Therapeutics
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of dotinurad in hyperuricemia and gout (2 arms), sponsored by Crystalys Therapeutics. Primary endpoint: Serum uric acid <6.0 mg/dL at Week 24. Planned start Oct 2025; status: authorised.
02
Drugs
dotinurad
03
Conditions
hyperuricemiagout
Beyond the preview
Go deeper on 2024-520206-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520206-19-00.